KPV

KPV is a naturally occurring tripeptide derived from the C-terminal end of alpha-melanocyte stimulating hormone (α-MSH). Despite being only three amino acids long, KPV retains the potent anti-inflammatory properties of the full α-MSH molecule without the melanogenic (tanning) or steroidogenic effects. It has shown promise in inflammatory bowel disease and general inflammation management.

KPV enters cells and directly interacts with inflammatory signaling pathways in the nucleus. It inhibits NF-κB activation by preventing the phosphorylation and degradation of IκBα, reducing the transcription of pro-inflammatory genes. It also reduces the expression of inflammatory cytokines (TNF-α, IL-6, IL-1β) and has antimicrobial properties. Unlike its parent molecule α-MSH, KPV does not activate melanocortin receptors at typical doses.

Studies demonstrate potent anti-inflammatory effects in colitis models (reduced colonic inflammation scores by 60-70%), skin inflammation, and arthritis models. Oral administration showed efficacy in IBD models — unusual for a peptide, suggesting GI stability or local action. PLA-nanoparticle formulations enhanced oral bioavailability. In vitro studies confirm NF-κB inhibition at nanomolar concentrations. No human clinical trials completed.

Peptides commonly paired with KPV for synergistic effects.